Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zuojin Wan + Dual Therapy for H. pylori Gastritis
NCT06901375Phase 1Not yet recruiting
- Sponsor
- Nanjing First Hospital
- Start
- May 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of zuojin wan in Helicobacter pylori infection and chronic gastritis (2 arms), sponsored by Nanjing First Hospital. Primary endpoints: Change from Baseline in functional dyspepsia symptoms at 6 weeks and Change in Traditional Chinese Medicine syndromes at 6 weeks. Planned start May 2025; status: not yet recruiting.
02
Drugs
zuojin wan
03
Conditions
Helicobacter pylori infectionchronic gastritis
Beyond the preview
Go deeper on NCT06901375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06901375.